Gilead Sciences Inc. (GILD)

Oncology Corporate Profile

Stock Performance

100.7200
-0.6100

HQ Location

333 Lakeside Drive
Foster City, CA 94404

Company Description

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide.

Website: http://www.gilead.com/

Brand Generic Indication
Zydelig®IdelalisibZydelig® is indicated in combination with rituximab for patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy and as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies. Accelerated approval was granted for FL and SLL based on overall response rate. Zydelig® is a first-in-class inhibitor of PI3K delta, a protein that is over-expressed in many B-cell malignancies and plays a role in the viability, proliferation and migration of these cancer cells.
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
GS-1101 (CAL-101)PI3K inhibitor1st line metastatic Chronic Lymphocytic Leukemia (CLL)III
Idelalisibp13k delta inhibitorChronic Lymphocytic Leukemia (CLL)III
GS-5745MMP9 mAb inbitorGastric cancerIII
momelotinibJAK inhibitorMyelofibrosisIII
entospletinibSyk inhibitorAcute Myelogenous Leukemia (AML)II
GS-4059BTK inhibitorB-cell malignanciesII
GS-6624monoclonal antibody (humanized)Colorectal cancerII
simtuzumabmonoclonal antibodyColorectal cancerII
CYT387JAK inhibitorMyelofibrosisII
simtuzumabmonoclonal antibodyMyelofibrosisII
GS-6624monoclonal antibody (humanized)Pancreatic cancerII
simtuzumabmonoclonal antibodyPancreatic cancerII
momelotinibJAK inhibitorPancreatic cancerII
GS-9973syk inhibitorVarious cancer typesII
entospletinibSyk inhibitorVarious cancer typesII
GS-9901p13k delta inhibitorVarious cancer typesI

View additional information on product candidates here »

Source: http://www.gilead.com/

Recent News Headlines

6/22/2017 06:18 pm

6/22/2017 06:18 pm

6/22/2017 06:18 pm

6/22/2017 06:18 pm

6/22/2017 06:18 pm

6/22/2017 12:19 pm

6/22/2017 12:19 pm

6/22/2017 12:19 pm

6/22/2017 12:19 pm

6/22/2017 12:19 pm

6/21/2017 12:19 pm

6/21/2017 12:19 pm

6/21/2017 12:19 pm

6/21/2017 12:19 pm

6/21/2017 06:18 am

6/20/2017 12:19 pm

6/20/2017 06:19 am

6/20/2017 06:19 am

6/20/2017 06:19 am

6/20/2017 06:19 am

6/19/2017 12:18 pm

6/19/2017 06:18 am

6/19/2017 06:18 am

6/18/2017 06:18 am

6/16/2017 12:20 pm